Overview of phase III clinical trials with non-vitamin K-dependent new oral anticoagulants (NOACs) for the acute-phase treatment and standard duration of anticoagulation after VTE
 |
|
b.i.d. = bis in die (twice daily); CRNM = clinically relevant non-major; DVT= deep vein thrombosis; o.d. = omni die (once daily); PE= pulmonary embolism; UFH = unfractionated heparin; VTE = venous thromboembolism.
a Approved doses of dabigatran are 150 mg b.i.d. and 110 mg b.i.d.
Overview of phase III clinical trials with non-vitamin K-dependent new oral anticoagulants (NOACs) for the acute-phase treatment and standard duration of anticoagulation after VTE
|
|
b.i.d. = bis in die (twice daily); CRNM = clinically relevant non-major; DVT= deep vein thrombosis; o.d. = omni die (once daily); PE= pulmonary embolism; UFH = unfractionated heparin; VTE = venous thromboembolism.
a Approved doses of dabigatran are 150 mg b.i.d. and 110 mg b.i.d.
